The addition of corticotropin-releasing hormone to 2-day low dose dexamethasone suppression test provides additional case detection.

Abstarct: PURPOSE: The diagnostic value of adding a Corticotropin-Releasing Hormone (CRH) Stimulation Test to the 2-day Low Dose Dexamethasone Suppression Test (Dex-CRH Test) has been debated in the literature.

Methods: We identified 65 patients with Cushing disease (CD) and 42 patients in whom a diagnosis of Cushing disease could not be confirmed (NCD) after a minimum follow-up of 14 months who underwent the Dex-CRH test.

Results: The female sex ratio, median (range) age, and BMI were similar between the two groups.

Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration.

Context: Recombinant human thyrotropin (rhTSH) is currently not Food and Drug Administration approved for the treatment of high-risk patients with differentiated thyroid cancer (DTC).

Objective: The goal of our study was to compare the outcomes in higher-risk patients with metastatic DTC prepared for radioiodine (RAI) therapy with rhTSH vs thyroid hormone withdrawal (THW).

Methods: A retrospective chart review was performed of patients with metastatic DTC in follow-up at MedStar Washington Hospital Center and MedStar Georgetown University Hospital from 2009 to 2017.

SHBG, Bone Mineral Density, and Physical Function Among Injection Drug Users With and Without HIV and HCV.

Context: Sex hormone-binding globulin (SHBG) is a glycoprotein that regulates the bioavailability of sex hormones and is higher in people with HIV (PWH) and hepatitis C virus (HCV). SHBG is associated with aging-related diseases, including osteoporosis and frailty in the general population. However, the relationship between SHBG concentration and bone mineral density (BMD) and physical function among PWH and HCV is unclear.

Hypogonadism in opioid using males in an inner-city cohort: A cross-sectional study.

Objectives: The link between male hypogonadism and opioids is well-established, but whether there is a difference in the frequency of hypogonadism between heroin and methadone for treatment of opioid use disorder (OUD) has not been -determined.

Design: Cross-sectional. Setting, patients, and participants: Male drug users and nonusers matched for socioeconomic status between 18 and 65 years, recruited in Baltimore as part of the study of HIV, injection drug use, nutrition, and endocrinology (SHINE).

Preoperative BMI Predicts Postoperative Weight Gain in Adult-onset Craniopharyngioma.

Context: Craniopharyngiomas, while benign, have the highest morbidity of all nonmalignant sellar tumors. Studies on weight and metabolic outcomes in adult-onset craniopharyngioma (AOCP) remain sparse.

Objective: To examine postsurgical weight and metabolic outcomes in AOCP and to identify any clinical predictors of weight gain.

Opioids and the Hypothalamic-Pituitary-Gonadal (HPG) Axis.

Context: Hypogonadism is a well-established consequence of opioid use. It has been reported in both men and women, although more widely studied in men.

Evidence Acquisition: PubMed was searched for articles in English until December 2019 for opioids and hypogonadism.

Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease.

Introduction: Hypophysitis is a rare disorder, defined as inflammation of the pituitary gland that may result in pituitary enlargement and varying anterior and posterior pituitary hormonal deficits. It involves different histopathological subtypes and variable etiologies, with considerable overlap between classification systems. Histopathology is the gold standard diagnostic approach.